Apply to join the ENABLE-2 consortium

New Open call launched December 20, 2022

ENABLE-2 is accepting molecules with direct acting systemic antibacterial activity and a novel mode of action targeting the ESKAPE pathogens: carbapenem-resistant EnterobacteriaceaeP. aeruginosa, A. baumannii; methicillin-resistant S. aureus; vancomycin-resistant E. faecium. Priority will be given to Gram-negative programmes.

Call closes Sunday January 8, 2023.

How to apply to ENABLE-2

The ENABLE-2 platform offers further development of Hits up to a level of advancement where they can successfully graduate to later stage initiatives (e.g., CARB-X, GARDP, REPAIR Impact Fund) or to out-licensing.

Novel modes of action can include action at a novel target, a novel mechanism of action against a known target, or a known mechanism of action against a known target so long as there is demonstrated activity against target-based resistant strains and management of known liabilities is appropriate.


Academics and SMEs within Sweden are eligible to submit a three-page Expression of Interest (EoI) to the ENABLE-2 platform with details of their anti-bacterial programme. SMEs receiving a positive evaluation from the PMC, and after completion of a description of work (DoW) with input from the ENABLE-2 management team may have the opportunity to apply for funding from VINNOVA.

Publicly funded universities from Europe are also eligible to submit a three-page Expression of Interest (EoI) to the ENABLE-2 platform.


Molecules/series with a novel mode of action targeting in-scope pathogens

  • direct acting small molecules and natural products for systemic activity
  • potentiation effect possible (eg beta-lactamase inhibitors)
  • activity against resistant clinical strains
  • single pathogen spectrum possible

Minimum inhibitory concentration (MIC) ≤ 16 μg/mL vs. at least one of the key ENABLE-2 pathogens

  • E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus, E. faecium
  • specific antibacterial activities (activities not due to broad cytotoxicity)

Potential for optimization

  • proven chemical structure and preliminary Structure–Activity Relationship
  • reasonable route of synthesis (or proven availability if a Natural Product)
  • favorable chemical properties allowing iv and/or oral administration
  • clear legal/IP situation

Download EoI template

​After you submit your EoI


Anders Karlén, Coordinator, Professor
Uppsala University (SE), +46 (0)70-167 9177 

Last modified: 2022-12-19